The ability to explain bleeding or clotting complications in patients treated with dabigatran
remains challenging. In addition, there is limited data on how coagulation tests perform in
patients treated with therapeutic doses of dabigatran. Predicted responses of coagulation
tests to therapeutic doses of dabigatran may be helpful in better understanding abnormal
responses to dabigatran. The purpose of the study is to define a therapeutic reference range
for peak and trough coagulation tests in patients taking FDA approved doses of dabigatran and
to determine which tests may be most clinically useful for monitoring dabigatran.